The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial

Lærke K Tolstrup, Lars Bastholt, Karin B Dieperink, Sören Möller, Ann-Dorthe Zwisler, Helle Pappot, Lærke K Tolstrup, Lars Bastholt, Karin B Dieperink, Sören Möller, Ann-Dorthe Zwisler, Helle Pappot

Abstract

Background: A randomized controlled pilot trial was conducted to assess if melanoma patients treated with immunotherapy had the number of grade 3 or 4 adverse events during treatment reduced by 50% using a tailored electronic patient-reported outcomes tool in addition to standard toxicity monitoring compared to standard monitoring alone. Secondary endpoints were: if more AEs were reported in the intervention group, if there was a difference between the two groups in the number of telephone consultations, extra out-patient visits, number of days in the hospital, days in steroid treatment and the time patients experienced grade 2 or higher toxicity.

Patients and methods: Melanoma patients receiving immunotherapy at the Department of Oncology, Odense University Hospital, Denmark participated. Standard care included assessment of AEs by a clinician before each treatment cycle using the Common Terminology Criteria for Adverse Events. In addition, patients randomized to the intervention reported their AEs weekly by an electronic PRO-tool based on the PRO-CTCAE platform.

Results: One hundred forty-six melanoma patients were randomized. In this study, we did not detect a difference between the two groups in the number of grade 3 or 4 AEs (P = 0.983), in the overall number of AEs (P = 0.560) or in the time the patients in the two groups experienced grade 2 or higher toxicity (0.516). The number of phone contacts was significantly higher in the intervention group (P = 0.009) and there was a tendency towards patients in the intervention group having more extra visits (P = 0.156).

Conclusion: It has been examined if the number of severe AEs for melanoma patients receiving immunotherapy could be reduced by involving the patients in the reporting of symptoms. The results do not justify the expansion of the pilot study into a regular phase III study with this particular set-up. However, a significant difference in the number of phone contacts was found as patients in the intervention group called more frequently, indicating that their attention to AEs was increased. Even though the use of an electronic PRO tool could not reduce the number of severe AEs in this melanoma population, a positive impact on other endpoints such as QoL, communication, or treatment-planning, cannot be excluded.

Trial registration: Clinicaltrials.gov NCT03073031 Registered 8 March 2017, Retrospectively registered.

Keywords: Adverse events; E-health; Immunotherapy; Melanoma; PRO; Patient involvement; Patient-reported outcomes; RCT; Toxicity.

Conflict of interest statement

The authors indicated no potential conflict of interest.

Figures

Fig. 1
Fig. 1
Example of patient reporting available to clinicians
Fig. 2
Fig. 2
Consort diagram of inclusion process
Fig. 3
Fig. 3
Duration of grade 2 or higher adverse events

References

    1. Matthews NH LW, Qureshi AA, et al. . Epidemiology of Melanoma. In: Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy [Internet]. Brisbane (AU): Codon Publications; 2017 Dec 21. Chapter 1. Available from: 2017.
    1. Helvind NM, Hölmich LR, Smith S, Glud M, Andersen KK, Dalton SO, et al. Incidence of in situ and invasive melanoma in Denmark from 1985 through 2012: A National Database Study of 24,059 melanoma cases. JAMA Dermatology. 2015;151(10):1087–1095. doi: 10.1001/jamadermatol.2015.1481.
    1. KræftensBekæmpelse. Statistik om modermærkekræft . Accessed 3 Dec 2019.
    1. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. European Journal of Cancer (Oxford, England : 1990) 2016;63:201–217. doi: 10.1016/j.ejca.2016.05.005.
    1. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. The New England Journal of Medicine. 2017;377(19):1824–1835. doi: 10.1056/NEJMoa1709030.
    1. Hall ET, Singhal S, Dickerson J, Gabster B, Wong HN, Aslakson RA, et al. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review. Journal of pain and symptom management. 2019;58(1):137–56.e1. doi: 10.1016/j.jpainsymman.2019.03.015.
    1. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Annals of Oncology. 2016;27(4):559–574. doi: 10.1093/annonc/mdv623.
    1. Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer (Oxford, England : 1990) 2019;119:1–10. doi: 10.1016/j.ejca.2019.07.001.
    1. Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., et al. (2016). Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncology, 17, 1558-1568.
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi: 10.1056/NEJMoa1504030.
    1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New England Journal of Medicine. 2015;372(4):320–330. doi: 10.1056/NEJMoa1412082.
    1. Weber, J. S., Gibney, G., Sullivan, R. J., Sosman, J. A., Slingluff Jr., C. L., Lawrence, D. P., et al. (2016). Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An open-label, randomised, phase 2 trial. The Lancet Oncology, 17, 943-955.
    1. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017;28(suppl_4):iv119–iiv42. doi: 10.1093/annonc/mdx225.
    1. NCI. Common Terminology Criteria for Adverse Events (CTCAE) . Accessed 3 Dec 2019.
    1. Mooney K, Whisenant MS, Beck SL. Symptom Care at Home: A Comprehensive and Pragmatic PRO System Approach to Improve Cancer Symptom Care. Medical Care. 2019;57(Suppl 5 Suppl 1):S66–s72. doi: 10.1097/MLR.0000000000001037.
    1. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Seminars in Oncology. 2010;37(5):499–507. doi: 10.1053/j.seminoncol.2010.09.007.
    1. Denis, F., Lethrosne, C., Pourel, N., Molinier, O., Pointreau, Y., Domont, J., et al. (2017). Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients. Journal of the National Cancer Institute, 109(9), 1-8.
    1. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine Cancer treatment: A randomized controlled trial. Journal of Clinical Oncology. 2016;34(6):557–565. doi: 10.1200/JCO.2015.63.0830.
    1. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine Cancer treatment. Jama. 2017;318(2):197–198. doi: 10.1001/jama.2017.7156.
    1. Fiteni F, Cuenant A, Favier M, Cousin C, Houede N. Clinical Relevance of Routine Monitoring of Patient-reported Outcomes Versus Clinician-reported Outcomes in Oncology. In vivo (Athens, Greece) 2019;33(1):17–21.
    1. Tolstrup LK, Bastholt L, Zwisler A-D, Dieperink KB, Pappot H. Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. Journal of Patient-Reported Outcomes. 2019;3(1):19. doi: 10.1186/s41687-019-0111-8.
    1. Arnold DM, Burns KE, Adhikari NK, Kho ME, Meade MO, Cook DJ. The design and interpretation of pilot trials in clinical research in critical care. Crit Care Med. 2009;37(1 Suppl):S69–S74. doi: 10.1097/CCM.0b013e3181920e33.
    1. OPEN. . Accessed 3 Dec 2019.
    1. Svane Inge Marie, Schmidt Henrik, Lars B. Vurdering og håndtering af bivirkninger relateret til immunterapi med ckeck-point hæmmere . Accessed 3 Dec 2019.
    1. Schougaard, L. M., Larsen, L. P., Jessen, A., Sidenius, P., Dorflinger, L., de Thurah, A., et al. (2016). AmbuFlex: tele-patient-reported outcomes (telePRO) as the basis for follow-up in chronic and malignant diseases. Quality of Life Research, 25, 525-534.
    1. Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., et al. (2016). Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol, 13, 473-486.
    1. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of Clinical Oncology. 2014;32(10):1020–1030. doi: 10.1200/JCO.2013.53.0105.
    1. Basch, E., Reeve, B. B., Mitchell, S. A., Clauser, S. B., Minasian, L. M., Dueck, A. C., et al. (2014). Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Journal of the National Cancer Institute, 106(9), 1-11.
    1. NCI. . Accessed 3 Dec 2019.
    1. Baeksted C, Nissen A, Pappot H, Bidstrup PE, Mitchell SA, Basch E, et al. Danish translation and linguistic validation of the U.S. National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) J Pain Symptom Manag. 2016;52(2):292–297. doi: 10.1016/j.jpainsymman.2016.02.008.
    1. Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, et al. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. Clinical Trials (London, England) 2017;14(3):255–263. doi: 10.1177/1740774517698645.
    1. Lee EC, Whitehead AL, Jacques RM, Julious SA. The statistical interpretation of pilot trials: Should significance thresholds be reconsidered? BMC Med Res Methodol. 2014;14(1):41. doi: 10.1186/1471-2288-14-41.
    1. StataCorp . Stata Statistical Software: Release 15. College Station: StataCorp LLC; 2017.
    1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine. 2010;363(8):711–723. doi: 10.1056/NEJMoa1003466.
    1. Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, et al. Patient-reported outcomes in routine cancer clinical practice: A scoping review of use, impact on health outcomes, and implementation factors. Annals of Oncology. 2015;26(9):1846–1858. doi: 10.1093/annonc/mdv181.
    1. Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, et al. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. Journal of Clinical Oncology. 2007;25(34):5374–5380. doi: 10.1200/JCO.2007.11.2243.
    1. Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: Algorithms for management. American Society of Clinical Oncology Educational Book. 2018;38:13–19. doi: 10.1200/EDBK_100013.
    1. Becker H, Roberts G, Voelmeck W. Explanations for improvement in both experimental and control groups. West J Nurs Res. 2003;25(6):746–755. doi: 10.1177/0193945903253002.
    1. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine. 2015;372(21):2006–2017. doi: 10.1056/NEJMoa1414428.
    1. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. The Lancet Oncology. 2015;16(8):908–918. doi: 10.1016/S1470-2045(15)00083-2.
    1. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2015;372(26):2521–2532. doi: 10.1056/NEJMoa1503093.
    1. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncology. 2019;5(7):1008–1019. doi: 10.1001/jamaoncol.2019.0393.
    1. de Bruin M, Viechtbauer W, Hospers HJ, Schaalma HP, Kok G. Standard care quality determines treatment outcomes in control groups of HAART-adherence intervention studies: Implications for the interpretation and comparison of intervention effects. Health Psychology. 2009;28(6):668–674. doi: 10.1037/a0015989.
    1. Tolstrup LK, Pappot H, Bastholt L, Zwisler A-D, Dieperink KB. Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients' and Clinicians' Experiences. Journal of Medical Internet Research. 2020;22(4):e14896–e1489e. doi: 10.2196/14896.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe